drugset / Trial / NCT05085444
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
NaSingle-groupOpen-labelTreatment
Summary
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
Timeline
- Start
- 2021-10-08
- Primary completion
- 2024-10-08
- Completion
- 2024-10-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19/BCMA CAR T-cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CD19/BCMA CAR T-cells | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | CD19/BCMA CAR T-cells | Cell therapy | 3e+06 cells/kg | Intravenous |
| Subject | CD19/BCMA CAR T-cells | Cell therapy | 4e+06 cells/kg | Intravenous |